Emerging Trends to Reshape the Intravenous Immunoglobulin Market: GC Pharma Launches Innovative Liquid Immune Globulin Formulation For Immunodeficiency Treatment as a Key Influencer

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

Intravenous Immunoglobulin Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for intravenous immunoglobulin has significantly increased in the past years. Its growth is projected to continue from a valuation of $14.66 billion in 2024 to an estimated $15.72 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%. The historical growth can be credited to its use in treating primary immunodeficiency disorders and managing neurological issues, along with a growing elderly population, progress in plasma fractionation techniques, broader neurological indications, and its application in treating infectious diseases and pediatric immunodeficiency.

Intravenous Immunoglobulin Market Size Forecast: What's the Projected Valuation by 2029?
Expectations are high for the intravenous immunoglobulin market, with robust growth predicted for the coming years. By 2029, this market is projected to reach $22.01 billion, thanks to a compound annual growth rate (CAGR) of 8.8%. This anticipated growth can be ascribed to several factors, such as the mounting prevalence of autoimmune disorders, ongoing immunology research, increased spending on healthcare, a rise in cancer incidence, innovative improvements in immunoglobulin products, and the implementation of personalized medicine guidance. Key trends to watch in this period include treatments for primary immunodeficiency disorders (PIDD), rapid advancements in technology, strategic partnerships, refinements in manufacturing processes, neurological indications, applications in the field of hematology, and progress in immunotherapy.

View the full report here:
https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

What Are the Drivers Transforming the Intravenous Immunoglobulin Market?
The intravenous immunoglobulin market is anticipated to be propelled by the rising elderly population. Typically, this denotes individuals who are 65 years old or older. As individuals age, their immune system may not operate as efficiently and may have a deficiency in antibodies. Consequently, they require immunoglobulins to supply them with these necessary antibodies. Such need bolsters the demand for intravenous immunoglobulins, thus spurring the intravenous immunoglobulin market. For instance, the Population Reference Bureau, a Nonprofit organization based in Kenya, anticipated in January 2024 that the population of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, reflecting a 47% rise. Accordingly, this age group's proportion of the total population is also expected to climb from 17% to 23% within the same timeframe. This increase in the elderly population is, therefore, predicted to steer the growth of the intravenous immunoglobulin market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

What Long-Term Trends Will Define the Future of the Intravenous Immunoglobulin Market?
One significant trend rapidly gaining momentum in the intravenous immunoglobulin market is product invention. Many prime market players are dedicating their focus on pioneering unique products like liquid immune globulin formulations, specifically to combat immunodeficiency diseases, thereby securing their market standing. As an illustration, GC Pharma, a pharmaceutical firm based in South Korea, introduced a new product called Alyglo in December 2023, which received approval from the US Food and Drug Administration (FDA). Alyglo, a sterile, user-ready liquid formulation contains 10% immunoglobulin G (IgG), offering 100mg/mL of protein, with at least 96% of it being human IgG obtained from a mix of human plasma. It is specifically designed for treating primary humoral immunodeficiency (PI) in adults who are 17 years and above. This product is useful for treating conditions like congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID).

Which Segments in the Intravenous Immunoglobulin Market Offer the Most Profit Potential?
The intravenous immunoglobulin market covered in this report is segmented -

1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications
4) By End-User: Hospitals, Clinics, Home Care

Subsegments:
1) By Immunoglobulin G (IgG): Normal IgG, Specific IgG
2) By Immunoglobulin M (IgM): Normal IgM, Specific IgM
3) By Immunoglobulin A (IgA): Normal IgA, Specific IgA
4) By Immunoglobulin E (IgE): Normal IgE, Specific IgE
5) By Immunoglobulin D (IgD): Normal IgD, Specific IgD

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=8538&type=smp

Which Firms Dominate the Intravenous Immunoglobulin Market by Market Share and Revenue in 2025?
Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

Which Regions Offer the Highest Growth Potential in the Intravenous Immunoglobulin Market?
North America was the largest region in the intravenous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8538

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.